Liver Transplantation after Successful Downstaging of a Locally Advanced Hepatocellular Carcinoma with Systemic Therapy

Introduction: Liver transplantation (LT) is potentially curative for patients with cirrhosis and hepatocellular carcinoma (HCC). However, this procedure is usually reserved for patients with early tumor stages or after successful downstaging with local regional therapies. In patients with locally advanced HCC, current guidelines recommend locoregional and palliative systemic therapies for tumor stages Barcelona Clinic Liver Cancer (BCLC) B and C, respectively. Case Report: In this article, we describe a 63-year-old male patient with locally advanced HCC (BCLC C) and hepatitis C-associated cirrhosis. Following systemic treatment with the immune checkpoint inhibitor atezolizumab and the anti-VEGF antibody bevacizumab, significant downstaging to a tumor stage within the Milan criteria was achieved after which LT was successfully performed. Conclusion: As more effective systemic therapies become available, LT and potential curative treatment could become feasible for selected patients with locally advanced HCC.

[1]  J. Bruix,et al.  Reply to: "Correspondence on the ". , 2022, Journal of hepatology.

[2]  F. Piscaglia,et al.  Experience with regorafenib in the treatment of hepatocellular carcinoma , 2021, Therapeutic advances in gastroenterology.

[3]  A. Zhu,et al.  Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[5]  J. Dufour,et al.  Immunotherapy as a Downstaging Therapy for Liver Transplantation , 2020, Hepatology.

[6]  S. Chopra,et al.  Checkpoint Inhibitor–Induced Rejection of a Liver Allograft: A Combination of Acute T Cell–Mediated and Antibody‐Mediated Rejection , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[9]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[10]  J. Roberts,et al.  Excellent Outcomes of Liver Transplantation Following Down‐Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  H. Tilg,et al.  Excellent post‐transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy , 2016, Liver international : official journal of the International Association for the Study of the Liver.